TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Freedom from major adverse limb events (MALEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Trait stress/mood: self-report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Responses to acute stress: self-report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Trait stress/mood: hypothalamic-pituitary-adrenal axis activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Responses to acute stress: hypothalamic-pituitary-adrenal axis activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Responses to acute stress: sympathetic-adrenal-medullary pathway activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Development of overt nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of rozanolixizumab in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Best response by analysis using Response Evaluation Criteria in Solid Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in laboratory parameters and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre- and post-injection vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Telomere length change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EpiAge clock change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal sensitive and responsive care change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal Knowledge of Social and Emotional Development change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: total hospitalization for DRESS duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Diagnostic yield of lung forcep biopsy and TBCB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of lung forcep biopsy and TBCB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Tests Taken Per Participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Positive SARS-CoV-2 BinaxNOW Tests Confirmed by PCR Testing
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with low cardiac output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall intensity of the symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms relief (skin irritation, pain, dryness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ClinESSDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sinonasal outcome test - 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lund Kennedy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total polyp score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rhinosinusitis Disability Index Score (RSDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean of Burning Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of Mouth Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of Tongue Protrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease activity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of proven and probable IFIs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of proven and probable breakthrough IFI
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sedative dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope, R^2 and bias at medical decision points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Alendronate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Alendronate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-Life (t1/2) of Alendronate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of omental metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to reach proficiency settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of trueness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Position of the needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Insomnia Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: motor function using the HFMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline urinary incontinence severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline urinary incontinence quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Kegel exercise compliance level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving MCID in VAS score from baseline to 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants reporting investigational-product-related AEs at 24 months
Endpoint domain: Adverse events/effects
Primary endpoint: Health Education Impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Illness Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Activation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Body Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of participants died
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coronary care unit admission
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants who used condom during their last sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who obtained PrEP prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who are willing to take PrEP in the next 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who took PrEP through pill or injection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: lateral neck flexor endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Helicobacter H. pylori eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in active range of motion of shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in passive range of motion of shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Depression, Anxiety, and Stress Scale, Youth (DASS-Y)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Harkavy-Asnis Suicide Scale (HASS), Suicide Attempt Module (HASS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Concise Health Risk Tracking (CHRT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in nocturnal blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cardiovascular disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endometrial Cancer Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Provider knowledge of sleep health
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Provider perceptions of sleep health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider practices regarding sleep health
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: opioid (morphine) consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) through assessment of dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of IO-108 RP2D
Endpoint domain: Adverse events/effects
Primary endpoint: CIN2+ incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-reported use of KOKU
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of tumor associated tissue eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apathy Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Propofol target concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in QT interval corrected using Fridericia's formula (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in the PR Interval (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in the QRS interval (QRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Menopause Rating Scale (MRS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of patients eligible for trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hormonal change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change in modified-OSATS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose-Light Level (MTDL)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of life in Neurological Disorders (Neuro-QoL) Version 2 Cognitive Function scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in task-specific whole-brain functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-Confidence Scale (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social validity of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of patients who decide to join in an Ulcerative Colitis clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Ulcerative Colitis patients who remain in clinical trial until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of KCG measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of KCG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of OKCARDIO smartphone application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-regional recurrence free survival (LRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Neuropsychiatric Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mucosal IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: changes in mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with a Dose Limiting Toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Kinetics of endocannabinoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary UPF intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events related to tracer administration
Endpoint domain: Adverse events/effects
Primary endpoint: Impact on mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant's experience of using BiH App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GMT Anti-S IgG at baseline and after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT against SARS-Cov-2 pseudovirus (PVNT) Neutralizing antibody titer 50 at baseline and after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Length of the Achilles Tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Fibers of the Gastrocnemius Medialis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle GM During the Single Support Phase of Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of subjects with solicited local AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with solicited Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with unsolicited symptomatic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with AEs leading to withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: sST2 levels in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: copeptin levels in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chromogranin levels in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NGAL levels in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suPAR levels in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cystatin levels in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TR from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as assessed by the 39-item Parkinson's disease Questionnaire (PDQ-39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mobility and fall risk as assessed by the Timed Up & Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in lesion thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 30 day hospital free days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Plasma ketones concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in overall corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of first dose hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Change in scar appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in wound width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dry Eye Questionnaire Score (DEQS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fluorescein Tear Breakup Time (FBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurobehavioral Symptom Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Anxiety and Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of COVID-19 disease
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of hospitalisations due to COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC Pain3°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological function levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in self-assessment pain, stiffness, and physical function (WOMAC questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in self-assessment quality of life (SF-36 questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in knee pain on visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device- and procedure-related death
Endpoint domain: Mortality/survival
Primary endpoint: Major target limb amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinically-driven target vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in performance on trained computerized cognitive tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in performance on transfer computerized cognitive tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients developing Acute Respiratory Distress Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of ICU admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence rate of hypoglycaemia or severe hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Starting point of focal temporal epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of venous thromboembolic events (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Minimum diameter of the inferior vena cava (IVC-min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum diameter of the inferior vena cava (IVC-max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collapsibility index of the inferior vena cava (IVC-CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with treatment-emergent adverse events (TEAEs) leading to discontinuation of study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: biomarkers of obsessive compulsive disorder pathophysiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence and biologic behavior of CD4CAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Generalized Anxiety Disorder-7 scale from Baseline to Post-Intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Generalized Anxiety Disorder-7 scale from Baseline to Follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Morphine dose administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurovisual ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the curve of the plasma concentration-time curve of dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting-state functional connectivity (rsFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarette per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Individual assessment of groups
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective Physical Activity Minutes Per Week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subjective Physical Activity Minutes Per Week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status